Closing the Translational Gap in Inflammation and Immunology

A. Methodology

Our methodology combines three core capabilities

Functional Disease Atlas at Scale

We're building the world's largest functional perturbation atlas of immune disease, capturing not just cellular states but how patient cells actually respond to intervention and perturbation. Unlike genomic databases that capture only static potential, our atlas captures actual cellular behavior, the real determinant of therapeutic response.

Functional Disease Atlas
at Scale

Lab-in-the-Loop Perturbation

We systematically test therapeutic hypotheses against live patient material using high-throughput, functional readouts. This lab-in-the-loop approach allows us to resolve individual patient variation and identify the spanning biological mechanisms that drive disease across cohorts.

Lab-in-the-Loop
Perturbation

Active Learning for Immunology

By integrating AI-driven experimental design with functional patient data, we make immunology tractable at scale. Our AI learns from each experiment, continuously refining its predictions and accelerating the discovery of mechanisms that drive disease to better positioning for curative I&I programs and impact throughout the drug discovery and development value chain.

Active Learning for
Immunolog

B.How we work

The Challenge

Immune and inflammatory diseases affect hundreds of millions of patients worldwide, yet clinical success rates remain stubbornly low. Traditional drug discovery relies on simplified models and static snapshots that fail to capture the dynamic complexity of human immune biology. The result? High failure rates, billion-dollar losses, and patients left waiting for effective therapies.

Our Solution

GraphTx is pioneering a new approach to precision immunology. We front-load clinical development by identifying and validating drug targets in live patient samples, long before the clinical trial begins. Our AI-driven platform systematically captures, perturbs, and decodes patient immune biology at unprecedented scale, transforming chaotic cellular data into actionable therapeutic insights.

Our Impact

By validating biology in real human cells before significant capital deployment, we fundamentally change the risk profile of drug development. Therapies emerging from our platform enter the clinic with unprecedented biological validation, reducing failure rates, accelerating timelines, and ultimately delivering better medicines to patients faster.

C. Team